---
title: "DarioHealth Amends Preferred Stock Conversion Terms"
description: "DarioHealth Corp. has amended the conversion terms for its Series A-1, C, and D preferred stocks to accelerate their mandatory conversion into common stock or pre-funded warrants, allowing for accrued"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/258150940.md"
published_at: "2025-09-19T21:32:32.000Z"
---

# DarioHealth Amends Preferred Stock Conversion Terms

> DarioHealth Corp. has amended the conversion terms for its Series A-1, C, and D preferred stocks to accelerate their mandatory conversion into common stock or pre-funded warrants, allowing for accrued dividends. This move aims to streamline the capital structure without new securities issuance. Analysts rate DRIO stock as a Hold with a $0.50 target, while Spark's AI Analyst gives it a Neutral rating due to financial challenges and a bearish trend, despite some optimism from strategic initiatives. DarioHealth focuses on digital health solutions for chronic condition management.

DarioHealth ( (DRIO) ) has provided an update.

On September 18, 2025, DarioHealth Corp. amended and restated the certificates of designation for its Series A-1, Series C, and Series D preferred stocks. These changes were made to accelerate the mandatory conversion of preferred shares into common stock or pre-funded warrants, allowing holders to receive accrued dividends as well. This strategic move is expected to streamline the company’s capital structure without issuing new securities.

The most recent analyst rating on (DRIO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on DarioHealth stock, see the DRIO Stock Forecast page.

**Spark’s Take on DRIO Stock**

According to Spark, TipRanks’ AI Analyst, DRIO is a Neutral.

DarioHealth’s overall stock score is primarily impacted by its financial challenges, including ongoing losses and high leverage. While technical indicators suggest a bearish trend, the company’s strategic initiatives and leadership changes provide some optimism for future growth.

To see Spark’s full report on DRIO stock, click here.

**More about DarioHealth**

DarioHealth Corp. operates in the digital health industry, offering innovative solutions for chronic condition management. The company’s primary products focus on digital therapeutics and health monitoring tools, aiming to improve patient outcomes and reduce healthcare costs.

**Average Trading Volume:** 19,429

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $15.79M

### Related Stocks

- [DRIO.US - DarioHealth](https://longbridge.com/en/quote/DRIO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| “SaaS 已死，SaaS 到来”！Altman 预言 “全 AI 企业” 时代开启 | OpenAI CEO 奥尔特曼预言 “全 AI 企业” 将开启，AI 将从辅助工具进化为完全自主的执行者。OpenAI 产品很快将实现 100% 由 AI 编写代码，涵盖开发与决策全流程，标志着传统 “软件即服务（SaaS）” 模式向 “服 | [Link](https://longbridge.com/en/news/275993856.md) |
| DarioHealth 公司（NASDAQ:DRIO）空头头寸大幅减少 | DarioHealth Corp.（纳斯达克代码：DRIO）在 1 月 30 日的空头头寸显著下降，减少了 17.3%，降至 64,677 股。目前，该公司 1.0% 的股份被做空，基于每日平均交易量 7,270 股，覆盖天数比率为 8.9 | [Link](https://longbridge.com/en/news/276065223.md) |
| AI 圈内人士：比新冠更大的事情正在发生，人们还懵懂不知 | AI 技术的演进正在引发深刻的职业冲击，HyperWriteAI 首席执行官 Matt Shumer 指出，AI 已从辅助工具转变为独立执行者，能够自主完成复杂任务。随着技术突破的加速，AI 具备了构建下一代 AI 系统的能力，预示着技术进 | [Link](https://longbridge.com/en/news/276029817.md) |
| “AI 交易” 的关键变量：服务业敞口越高，AI 颠覆风险越大，“AI 基建” 最有利 | 大摩量化研究显示，“服务业敞口” 是 AI 投资的关键变量，与收益呈显著负相关。由于市场担忧 AI 颠覆，服务业敞口高达 53% 的 “AI 采用者” 表现垫底。相反，“AI 基础设施” 敞口仅 14%，受颠覆风险最小且受益于资本支出，在六 | [Link](https://longbridge.com/en/news/275977957.md) |
| 现在是否应该押注 SoundHound AI 股票的空头回补行情？ | 您现在应该押注于 SoundHound AI 股票的空头挤压吗？ | [Link](https://longbridge.com/en/news/275918992.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.